Compare Texas Instruments Incorporated (TXN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Texas Instruments Incorporated vs Zimmer Biomet Holdings Inc — how do they compare? Texas Instruments Incorporated trades at $290.02 (market cap $258.53B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Texas Instruments Incorporated is far larger — about 14.9× Zimmer Biomet Holdings Inc's market cap, and Texas Instruments Incorporated pays the higher dividend (2%). Which is the better fit depends on your goals.
| TXN | ZBH | |
|---|---|---|
Market Cap | $258.53B | $17.36B |
Sector | Technology | Health |
52-Week High | $332.35 | $107.71 |
52-Week Low | $153.33 | $79.58 |
Enterprise Value | $267.48B | $24.40B |
Dividend Yield | 2% | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Texas Instruments (TXN) trades at $284.02, down 2.47% over 24 hours, with technical signals leaning bearish. The company reported mixed recent earnings, beating Q1 2026 estimates but missing Q3 and Q4 2025. Revenue and net income have shown volatility, with 2025 figures at $17.68B and $5.00B respectively. Analysts maintain a consensus Buy rating with a $313.05 price target, indicating potential upside. Recent CFO transition news and AI-driven demand in data centers are key developments.
Outlook remains cautiously optimistic given strong profitability margins and analyst support, but risks include elevated valuation multiples and competitive pressures in the semiconductor sector. The stock's current price near support at $281 suggests a critical level for near-term direction.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
